---
title: "Chemotherapy-Associated Colitis After TCbHP in HER2-Positive Breast Cancer: Case Report"
id: "pubmed-42571049"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42571049"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42571049/"
doi: "10.12659/AJCR.952507"
published_at: "2026-08-09T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Chemotherapy-Associated Colitis After TCbHP in HER2-Positive Breast Cancer: Case Report
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42571049
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42571049/)
- **DOI:** [10.12659/AJCR.952507](https://doi.org/10.12659%2FAJCR.952507)
- **Published At:** 2026-08-09T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- A 53-year-old woman with invasive left breast carcinoma (pT2N0M0, Stage IIA) characterized as **ER-negative, PR-negative, HER2 3+** underwent total mastectomy and received adjuvant chemotherapy with the **TCbHP** regimen (docetaxel, carboplatin, trastuzumab, pertuzumab). - One week after the first TCbHP cycle she developed abdominal pain and diarrhea; colonoscopy confirmed **colitis**. This adverse event is presented as rare in the context of breast cancer chemotherapy. - During the second cycle the chemotherapy dose was reduced to 80%, but abdominal pain recurred; repeat colonoscopy showed **colonic ulcers**. - The treatment regimen was changed from TCbHP to **THP** (nab-paclitaxel, trastuzumab, pertuzumab). After this modification, symptoms resolved and follow-up colonoscopy demonstrated ulcer healing. - The authors emphasize that chemotherapy-induced colitis is an uncommon but potentially serious complication that can progress to necrosis and may require intestinal resection if not promptly managed. - Because this is a single case report and the patient received combination chemotherapy, a definitive causal relationship between a specific agent and colitis cannot be established from the presented data. - The report highlights the diagnostic and therapeutic challenges of chemotherapy-associated colitis and proposes timely regimen modification as a practical management approach in this case.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42571049/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42571049%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42571049/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42571049/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42571049/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42571049/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42571049/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42571049%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42571049%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42571049/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42571049/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42571049/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42571049/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42571049/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42571049/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42571049/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42571049/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42571049/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42571049/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42571049/#substances) Title & authors Abstract Similar articles Publication types MeSH terms Substances Case Reports Am J Case Rep Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Am+J+Case+Rep%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Am+J+Case+Rep%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) . 2026 Aug 9:27:e952507. doi: 10.12659/AJCR.952507. # Invasive Breast Cancer Complicated by Colitis After TCbHP Chemotherapy: A Case Report [Zicong You](https://pubmed.ncbi.nlm.nih.gov/?term=You+Z&cauthor_id=42571049)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#full-view-affiliation-1 "Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China."), [Yue Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+Y&cauthor_id=42571049)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#full-view-affiliation-2 "Department of Anesthesiology Operating Room, The First People's Hospital of Foshan, Foshan, Guangdong, China."), [Shiying Cao](https://pubmed.ncbi.nlm.nih.gov/?term=Cao+S&cauthor_id=42571049)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#full-view-affiliation-1 "Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China."), [Fei Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+F&cauthor_id=42571049)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#full-view-affiliation-1 "Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China.") Affiliations Expand ### Affiliations * 1 Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China. * 2 Department of Anesthesiology Operating Room, The First People's Hospital of Foshan, Foshan, Guangdong, China. * PMID: **42571049** * DOI: [ 10.12659/AJCR.952507 ](https://doi.org/10.12659/ajcr.952507) Item in Clipboard Case Reports # Invasive Breast Cancer Complicated by Colitis After TCbHP Chemotherapy: A Case Report Zicong You et al. Am J Case Rep. 2026. Show details Display options Display options Format Abstract PubMed PMID Am J Case Rep Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Am+J+Case+Rep%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Am+J+Case+Rep%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) . 2026 Aug 9:27:e952507. doi: 10.12659/AJCR.952507. ### Authors [Zicong You](https://pubmed.ncbi.nlm.nih.gov/?term=You+Z&cauthor_id=42571049)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#short-view-affiliation-1 "Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China."), [Yue Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+Y&cauthor_id=42571049)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#short-view-affiliation-2 "Department of Anesthesiology Operating Room, The First People's Hospital of Foshan, Foshan, Guangdong, China."), [Shiying Cao](https://pubmed.ncbi.nlm.nih.gov/?term=Cao+S&cauthor_id=42571049)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#short-view-affiliation-1 "Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China."), [Fei Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+F&cauthor_id=42571049)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42571049/#short-view-affiliation-1 "Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China.") ### Affiliations * 1 Department of Thoracic and Breast Surgery, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China. * 2 Department of Anesthesiology Operating Room, The First People's Hospital of Foshan, Foshan, Guangdong, China. * PMID: **42571049** * DOI: [ 10.12659/AJCR.952507 ](https://doi.org/10.12659/ajcr.952507) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract BACKGROUND Chemotherapy is a cornerstone of systemic treatment for breast cancer. Common adverse effects include nausea, vomiting, diarrhea, and myelosuppression; chemotherapy-induced colitis is rare, and its underlying mechanisms remain unclear. We aim to raise awareness of this uncommon but serious adverse event and describe a practical approach to regimen modification. CASE REPORT A 53-year-old woman underwent left total mastectomy for invasive breast carcinoma (pT2N0M0, Stage IIA; ER [-]/PR [-]/HER2 [3+]). She received adjuvant chemotherapy with the TCbHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab). One week after the first cycle, she developed abdominal pain and diarrhea. Colonoscopy revealed colitis. After dose reduction to 80% in the second cycle, abdominal pain recurred, and colonoscopy demonstrated colonic ulcers. The regimen was subsequently changed to THP (nab-paclitaxel, trastuzumab, and pertuzumab); symptoms then resolved, and follow-up colonoscopy showed ulcer healing. CONCLUSIONS Colitis associated with breast cancer chemotherapy is rare, presenting diagnostic and therapeutic challenges. Severe complications, including colonic necrosis, may develop if not promptly addressed. In the present case, timely intervention and regimen modification prior to the onset of intestinal necrosis appeared to prevent serious sequelae, including the need for intestinal resection. However, given the limitations of a single case report and the use of combination chemotherapy, a definitive causal relationship cannot be established. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. ](https://pubmed.ncbi.nlm.nih.gov/39612919/) Chen XC, Jiao DC, Qiao JH, Wang CZ, Sun XF, Lu ZD, Li LF, Zhang CJ, Yan M, Wei Y, Chen B, Feng YQ, Deng M, Ma MD, Plichta JK, He YW, Liu ZZ.Chen XC, et al.Lancet Oncol. 2025 Jan;26(1):27-36. doi: 10.1016/S1470-2045(24)00581-3. Epub 2024 Nov 26.Lancet Oncol. 2025.PMID: 39612919Clinical Trial. * [ Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. ](https://pubmed.ncbi.nlm.nih.gov/41576297/) Gao HF, Ye GL, Lin Y, Huang Q, Dong J, Cao Y, Zhao YX, Chen QJ, Ma SH, Ouyang J, Ye JH, Yang HW, Zhang YQ, Zhang YC, Zhang GL, Li W, Zhang Y, Wu ZY, Lin YY, Zhu T, Zhang LL, Yang CQ, Yang M, Peng H, Chen B, Chen YT, Ji F, Cheng MY, Li JQ, Jiang Z, Wang K.Gao HF, et al.J Clin Oncol. 2026 Jun 10;44(17):1587-1596. doi: 10.1200/JCO-25-02176. Epub 2026 Jan 23.J Clin Oncol. 2026.PMID: 41576297Free PMC article.Clinical Trial. * [ MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study. ](https://pubmed.ncbi.nlm.nih.gov/41713473/) Louis FM, van der Voort A, van Ramshorst MS, Daletzakis A, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJM, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Egeler MD, van de Poll-Franse LV, Mann RM, Sonke GS; Dutch Breast Cancer Research Group (BOOG).Louis FM, et al.Lancet Oncol. 2026 Mar;27(3):349-360. doi: 10.1016/S1470-2045(25)00707-7. Epub 2026 Feb 16.Lancet Oncol. 2026.PMID: 41713473Clinical Trial. * [ Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. ](https://pubmed.ncbi.nlm.nih.gov/34019819/) Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A; PHERGain steering committee and trial investigators.Pérez-García JM, et al.Lancet Oncol. 2021 Jun;22(6):858-871. doi: 10.1016/S1470-2045(21)00122-4. Epub 2021 May 18.Lancet Oncol. 2021.PMID: 34019819Clinical Trial. * [ Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis. ](https://pubmed.ncbi.nlm.nih.gov/40493995/) Yuan Y, Long X, Wei M, Chen L, Zhang J, Liu X.Yuan Y, et al.Cancer Treat Rev. 2025 Jul;138:102975. doi: 10.1016/j.ctrv.2025.102975. Epub 2025 Jun 5.Cancer Treat Rev. 2025.PMID: 40493995 [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42571049) ## Publication types * Case Reports Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Case+Reports%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Case+Reports) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) ## MeSH terms * Antibodies, Monoclonal, Humanized / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Humanized%2Fadministration+and+dosage%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal%2C+Humanized) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Antibodies, Monoclonal, Humanized / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Humanized%2Fadverse+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal%2C+Humanized) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Antineoplastic Combined Chemotherapy Protocols* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Breast Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Breast Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Carboplatin / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carboplatin%2Fadministration+and+dosage%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carboplatin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Carboplatin / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carboplatin%2Fadverse+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carboplatin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Chemotherapy, Adjuvant / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Chemotherapy%2C+Adjuvant%2Fadverse+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Chemotherapy%2C+Adjuvant) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Colitis* / chemically induced Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Colitis%2Fchemically+induced%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Colitis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Docetaxel / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Docetaxel%2Fadverse+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Docetaxel) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42571049/) * Mastectomy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mastectomy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mastectomy) * [ Add to Search ](ht
## Related Clinical Research

- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)
- [Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer](https://medichelpline.com/clinical-feed/nejm-11-trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer.md)
- [Sympathetic Overdrive, Vascular Dysfunction, and Exercise Intolerance in Long-Term Breast Cancer](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-65-sympathetic-neural-overactivation-vascular-dysfunction-and-exercise-intolerance-in-long-term-survivors-of-breast-cancer-treated-with-doxorubicin-and-trastuzumab-based-chemotherapy.md)
- [Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive](https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-23-neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-the-randomized-noninferiority-phase-iii-neocarhp-trial.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.